ESMO 2026 - Breast Cancer: Selective CDK4 with Dr. Antonio Giordano

After CDK4/6 progression, the search for new options continues. Dr. Antonio Giordano takes a closer look at FOURLIGHT-1 and atirmociclib plus fulvestrant in HR+/HER2-negative metastatic breast cancer.